Evolus Q2 revenue rises 4% to $69.4 mln

Evolus

05/08/2025 21:57

Overview

Evolus Q2 2025 global net revenue rises 4% to $69.4 mln

Company expects meaningful profitability in Q4 2025

Launch of Evolysse drives revenue growth amid U.S. market challenges

Outlook

Evolus expects 2025 revenue between $295 mln and $305 mln

Company anticipates Q4 2025 profitability and annual profitability in 2026

Evolus plans to launch Evolysse™ Sculpt in 2026 and Lips in 2027

Company targets $700 mln revenue and 20% margin by 2028

Result Drivers

EVOLYSSE LAUNCH - Evolysse generated $9.7 mln in Q2 2025, marking a strong debut in the filler market

INTERNATIONAL GROWTH - Strong international sales contributed significantly to revenue increase

U.S. MARKET CHALLENGES - U.S. toxin demand softened due to decreased consumer sentiment, impacting sales

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
$68.70 mln
Q2 Net Income
-$17.14 mln
Q2 Gross Margin
65.3%
Q2 Adjusted Gross Margin
66.5%
Q2 Gross Profit
$45.32 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Evolus Inc is $23.50, about 61.2% above its August 4 closing price of $9.11

The stock recently traded at 43 times the next 12-month earnings vs. a P/E of 56 three months ago

Press Release: ID:nBw9GDP4a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)